Education
About Us
Working with TipRanks
Follow Us
Omnicell (OMCL)
NASDAQ:OMCL
OMCL Stock Chart & Stats
$49.04
-$0.19(-0.44%)
At close: 4:00 PM EST
$49.04
-$0.19(-0.44%)
Day’s Range― - ―
52-Week Range$22.66 - $55.00
Previous CloseN/A
Volume97.52K
Average Volume (3M)459.68K
Market Cap
$2.20B
Enterprise Value$2.28B
Total Cash (Recent Filing)$193.45M
Total Debt (Recent Filing)$206.78M
Price to Earnings (P/E)115.1
Beta0.16
Next Earnings
Feb 05, 2026EPS Estimate
0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding44,876,522
10 Day Avg. Volume338,107
30 Day Avg. Volume459,681
Financial Highlights & Ratios
PEG Ratio-1.02
Price to Book (P/B)1.65
Price to Sales (P/S)1.84
P/FCF Ratio13.55
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue1.94
Enterprise Value/Gross Profit4.42
Enterprise Value/Ebitda19.38
Forecast
1Y Price Target
$55.60Price Target Upside13.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital Spending And FinancingImproved access to financing and recovering pharmacy IT and capital budgets should make it easier for hospitals and pharmacies to fund automation equipment purchases, lifting demand for dispensing and robotics products.
Platform And Recurring RevenueTitan XT combined with the OmniSphere cloud platform creates an enterprise-level, cloud-connected medication management system that enables central control, AI-driven insights and subscription services, supporting higher-margin recurring revenue.
Product Traction And Margin ExpansionMomentum in new offerings such as XTExtend, together with a salesforce build-out, is expected by analysts to accelerate sales conversion and contribute to margin expansion in FY26.
Bears Say
Customer Upgrade BehaviorCustomer preference for top-swap upgrades rather than full fleet replacements may limit the scale of new-system conversions and constrain revenue growth from fleet refresh cycles.
Tariff HeadwindsOngoing tariffs increase costs for equipment and medical supplies, raising the net tariff impact and exerting pressure on gross margins and profitability.
Valuation And Analyst SentimentAn analyst Neutral rating and a stock gain of over twenty percent suggest much of the anticipated product-cycle upside may already be priced in, reducing near-term upside without stronger execution.
Omnicell News
OMCL FAQ
What was Omnicell’s price range in the past 12 months?
Omnicell lowest stock price was $22.66 and its highest was $55.00 in the past 12 months.
What is Omnicell’s market cap?
Omnicell’s market cap is $2.20B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Feb 05, 2026 which is in 6 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Oct 30, 2025. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.362 by $0.148.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.5.
How many shares outstanding does Omnicell have?
Omnicell has 44,876,522 shares outstanding.
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of $0.51 in its last earnings report, beating expectations of $0.362. Following the earnings report the stock price went up 13.561%.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in OMCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omnicell Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.60 (13.38% Upside)
$55.60 (13.38% Upside)
Blogger Sentiment
Bullish
OMCL Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 7.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 17.5%
Last 30 Days ▲ 17.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.24%
12-Months-Change
Fundamentals
Return on Equity
1.62%
Trailing 12-Months
Asset Growth
-15.41%
Trailing 12-Months
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
OMCL Company Deck
OMCL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and successful execution against guidance, particularly in point-of-care solutions and the OmniSphere platform. However, there were notable challenges including a decrease in both GAAP and Non-GAAP EPS, tariff impacts on profitability, and slower growth in certain service revenues. Despite these challenges, the company's strategic initiatives and product adoption indicate positive momentum.View all OMCL earnings summariesOMCL Stock 12 Month Forecast
Average Price Target
$55.60
▲(13.38% Upside)
Technical Analysis
Ownership Overview
2.99% Insiders
27.34% Mutual Funds
0.73% Other Institutional Investors
36.40% Public Companies and
Individual Investors